Additionally, the effects of Nutlin-3 and other MDM2 antagonists have not been thoroughly assessed in prostate cancer cell lines that express alternative forms of AR or mutant p53, such as VCaP or 22Rv1, although a direct comparison between such cells would prove difficult due to their rather divergent lineage. Here, AR is linked to prostate cancer.